

Xeljanz - (5 mg; Tablet, Oral)

Generic Name	Tofacitinib	Innovator	Pfizer
Dosage	5 mg; Tablet, Oral	Branded US Sales	Less Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	More Than 5
Other ANDA developers	More Than 5	Tentative Approvals	More Than 5
Final Approvals	Less Than 5	Generic Launches	None
Indication	Used to treat moderate to severe rheumatoid arthritis or active psoriatic arthritis (PsA) in adults who have tried methotrexate other medications without successful treatment of symptoms		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.



Xeljanz - (10 mg; Tablet, Oral)

Generic Name	Tofacitinib	Innovator	Pfizer
Dosage	10 mg; Tablet, Oral	Branded US Sales	Less Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	More Than 5
Other ANDA developers	More Than 5	Tentative Approvals	More Than 5
Final Approvals	None	Generic Launches	None
Indication	Xeljanz is indicated for the treatment of adult patients with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact $\underline{contact@researchdelta.com} \ to \ get \ Detailed \ Information.$

Launch Timelines and Competition

Please Contact $\underline{contact@researchdelta.com}$ to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.



Xeljanz - (1 mg/mL; Oral Solution)

Generic Name	Tofacitinib	Innovator	Pfizer	
Dosage	1 mg/mL ; Oral Solution	Branded US Sales	Less Than \$1000 mn	
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5	
Other ANDA developers	Less Than 5	Tentative Approvals	Less Than 5	
Final Approvals	Less Than 5	Generic Launches	None	
Indication	XELJANZ/XELJANZ XR/XELJANZ Oral Solution is a Janus kinase (JAK) inhibitor indicated for: 1) Rheumatoid Arthritis - XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. 2) Psoriatic Arthritis - XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs). ? Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. 3) Ulcerative Colitis - XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC), who have had an inadequate response or who are intolerant to TNF blockers. 4) Polyarticular Course Juvenile Idiopathic Arthritis - XELJANZ/XELJANZ Oral Solution is indicated for the treatment of active polyarticular course juvenile idiopathic arthritis (pcJIA) in patients 2 years of age and older.			
Complexities	Yes			

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.



Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.